Country: Canada
Language: English
Source: Health Canada
METRONIDAZOLE
BAXTER CORPORATION
J01XD01
METRONIDAZOLE
5MG
SOLUTION
METRONIDAZOLE 5MG
INTRAVENOUS
15G/50G
Prescription
MISCELLANEOUS ANTIPROTOZOALS
Active ingredient group (AIG) number: 0102572002; AHFS:
APPROVED
2000-02-01
_METRONIDAZOLE INJECTION, USP Product Monograph _ _Page 1 of 33_ PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION PR METRONIDAZOLE INJECTION, USP Metronidazole Solution, 5 mg/mL and I.V. infusion USP Antibacterial-Antiprotozoal ATC J01XD01 Baxter Corporation 7125 Mississauga Road Mississauga Ontario Canada L5N 0C2 Date of Initial Authorization: DEC 31, 1990 Date of Revision: SEPT 20, 2022 Submission Control Number: 263478 _METRONIDAZOLE INJECTION, USP Product Monograph _ _Page 2 of 33_ RECENT MAJOR LABEL CHANGES 2 Contraindications 09/2022 TABLE OF CONTENTS SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF AUTHORIZATION ARE NOT LISTED. RECENT MAJOR LABEL CHANGES..............................................................................................2 TABLE OF CONTENTS.....................................................................................................................2 PART I: HEALTH PROFESSIONAL INFORMATION .......................................................................4 1 INDICATIONS ................................................................................................................4 1.1 Pediatrics .......................................................................................................... 4 1.2 Geriatrics .......................................................................................................... 5 2 CONTRAINDICATIONS ...................................................................................................5 4 DOSAGE AND ADMINISTRATION...................................................................................5 4.1 Dosing Considerations..................................................................................... 5 4.2 Recommended Dose and Dosage Adjustment .............................................. 5 4.4 Administration................................................................................................... 6 4.5 Missed Dose............................................................. Read the complete document